Related references
Note: Only part of the references are listed.Insights from pharmacological similarity of epigenetic targets in epipolypharmacology
J. Jesus Naveja et al.
DRUG DISCOVERY TODAY (2018)
Charting the Bromodomain BRD4: Towards the Identification of Novel Inhibitors with Molecular Similarity and Receptor Mapping
Fernando D. Prieto-Martinez et al.
LETTERS IN DRUG DESIGN & DISCOVERY (2018)
BET bromodomain proteins regulate enhancer function during adipogenesis
Jonathan D. Brown et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo
Matteo Aldeghi et al.
COMMUNICATIONS CHEMISTRY (2018)
Flavonoids as Putative Epi-Modulators: Insight into Their Binding Mode with BRD4 Bromodomains Using Molecular Docking and Dynamics
Fernando D. Prieto-Martinez et al.
BIOMOLECULES (2018)
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases
Hideaki Niwa et al.
EPIGENETICS (2017)
Exploring the epigenetic drug discovery landscape
Veda Prachayasittikul et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase
Yan Xiong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Beneficial effects of diazepin-quinazolin-amine derivative (BIX-01294) on preimplantation development and molecular characteristics of cloned mouse embryos
Yanfang Huang et al.
REPRODUCTION FERTILITY AND DEVELOPMENT (2017)
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity
Sandeep Sundriyal et al.
MEDCHEMCOMM (2017)
Epigenetic regulation by G9a/GLP complex ameliorates amyloid-beta 1-42 induced deficits in long-term plasticity and synaptic tagging/capture in hippocampal pyramidal neurons
Mahima Sharma et al.
AGING CELL (2017)
Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors
Mingfeng Shao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Structure-activity relationship studies of G9a-like protein (GLP) inhibitors
Yan Xiong et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
Chao Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery
Yuxi Wang et al.
FEBS JOURNAL (2016)
RVX-297-a novel BD2 selective inhibitor of BET bromodomains
Olesya A. Kharenko et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Regulation of cell differentiation and function by the euchromatin histone methyltranserfases G9a and GLP
Jamie M. Kramer
BIOCHEMISTRY AND CELL BIOLOGY (2016)
BET Bromodomain as a Target of Epigenetic Therapy
Tomomi Noguchi-Yachide
CHEMICAL & PHARMACEUTICAL BULLETIN (2016)
Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase
Kyle V. Butler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Unexpected Distinct Roles of the Related Histone H3 Lysine 9 Methyltransferases G9a and G9a-Like Protein in Myoblasts
Valentine Battisti et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells
Z. Lin et al.
MOLECULAR BIOSYSTEMS (2016)
Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers
Babak Alaei-Mahabadi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Epigenetic polypharmacology: from combination therapy to multitargeted drugs
Angel R. de Lera et al.
CLINICAL EPIGENETICS (2016)
Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features
Valentina Speranzini et al.
SCIENCE ADVANCES (2016)
Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase
Fan-Wei Peng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Histone deacetylases: structural determinants of inhibitor selectivity
Carmina Micelli et al.
DRUG DISCOVERY TODAY (2015)
Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response
Ramon Cacabelos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Potential of epigenetic therapies in the management of solid tumors
Victor Valdespino et al.
CANCER MANAGEMENT AND RESEARCH (2015)
Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans
Nicholas A. Malmquist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Epigenetic relevant chemical space: a chemoinformatic characterization of inhibitors of DNA methyltransferases
Eli Fernandez-de Gortari et al.
RSC ADVANCES (2015)
Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
Stuart W. J. Ember et al.
ACS CHEMICAL BIOLOGY (2014)
Bromodomains and Their Pharmacological Inhibitors
Daniel Gallenkamp et al.
CHEMMEDCHEM (2014)
Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
Anqi Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Properly Substituted Analogues of BIX-01294 Lose Inhibition of G9a Histone Methyltransferase and Gain Selective Anti-DNA Methyltransferase 3A Activity
Dante Rotili et al.
PLOS ONE (2014)
Structure-activity relationship studies of SETD8 inhibitors
Anqi Ma et al.
MEDCHEMCOMM (2014)
The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
Stephen J. Atkinson et al.
MEDCHEMCOMM (2014)
Spiro heterocycles as potential inhibitors of SIRT1: Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2′-quinazolines
D. Rambabu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Sarah Picaud et al.
CANCER RESEARCH (2013)
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
Benjamin E. L. Lauffer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The 2.5 Å Crystal Structure of the SIRT1 Catalytic Domain Bound to Nicotinamide Adenine Dinucleotide (NAD+) and an Indole (EX527 Analogue) Reveals a Novel Mechanism of Histone Deacetylase Inhibition
Xun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Christopher J. Millard et al.
MOLECULAR CELL (2013)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Histone Deacetylase Inhibitors: Structure-Based Modeling and Isoform-Selectivity Prediction
Laura Silvestri et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
Paul V. Fish et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Trials with 'epigenetic' drugs: An update
Angela Nebbioso et al.
MOLECULAR ONCOLOGY (2012)
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate
Peter J. Watson et al.
NATURE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum
Nicholas A. Malmquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
Thomas Beckers et al.
MEDCHEMCOMM (2012)
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Patrick M. Lombardi et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2011)
Chromatin modifying agents - the cutting edge of anticancer therapy
Faith A. A. Kwa et al.
DRUG DISCOVERY TODAY (2011)
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi et al.
NATURE CHEMICAL BIOLOGY (2011)
Involvement of Histone H3 Lysine 9 (H3K9) Methyltransferase G9a in the Maintenance of HIV-1 Latency and Its Reactivation by BIX01294
Kenichi Imai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Adding a Lysine Mimic in the Design of Potent Inhibitors of Histone Lysine Methyltransferases
Yanqi Chang et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization
S. Goyama et al.
LEUKEMIA (2010)
Quinazolines as novel anti-inflammatory histone deacetylase inhibitors
Zhigang Lin et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity
Ian Maze et al.
SCIENCE (2010)
Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
Yanqi Chang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
A combined chemical and genetic approach for the generation of induced pluripotent stem cells
Yan Shi et al.
CELL STEM CELL (2008)
Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells
Yutaka Kondo et al.
PLOS ONE (2008)
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas
Yutaka Kondo et al.
HEPATOLOGY RESEARCH (2007)
Phenotypic plasticity and the epigenetics of human disease
Andrew P. Feinberg
NATURE (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity
Bruce G. Szczepankiewicz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists.: 1.: Potent and selective small molecule CGRP antagonists.: 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine:: The first CGRP antagonist for clinical trials in acute migraine
K Rudolf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains
S Maurer-Stroh et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Alzheimer amyloid β-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus
QS Chen et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2002)
Overexpression. of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion
U Thorsteinsdottir et al.
BLOOD (2002)
Regulation of chromatin structure by site-specific histone H3 methyltransferases
S Rea et al.
NATURE (2000)
Share Paper
